ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
Dow Jones
39.908,00
0,88%
Euro vs US Dollar
1,0881
0,62%
Bitcoin
65.819,37
6,94%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ambrx Biopharma Inc (AMAM)

  7. Ambrx Biopharma Inc (AMAM) News

AMAM

Ambrx Biopharma (AMAM)

Ambrx Biopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AMAM
DatumZeitQuelleÜberschriftSymbolFirma
18/03/202419h45Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:AMAMAmbrx Biopharma Inc
12/03/202421h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
11/03/202405h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202419h39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202419h34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202419h29Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202419h24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202419h20Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
07/03/202419h23Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AMAMAmbrx Biopharma Inc
07/03/202414h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
06/03/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
23/02/202420h09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMAMAmbrx Biopharma Inc
22/02/202414h31Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMAMAmbrx Biopharma Inc
22/02/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
12/02/202419h43PR Newswire (US)Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmNASDAQ:AMAMAmbrx Biopharma Inc
10/01/202421h07PR Newswire (US)Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202420h54Dow Jones NewsTrending: Johnson & Johnson and Merck & Co. Announce AcquisitionsNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202416h04Dow Jones NewsAmbrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & JohnsonNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202414h12Dow Jones NewsJohnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 BillionNASDAQ:AMAMAmbrx Biopharma Inc
23/10/202323h19Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:AMAMAmbrx Biopharma Inc
15/09/202322h27Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:AMAMAmbrx Biopharma Inc
15/09/202322h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
06/09/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
25/08/202323h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
19/07/202315h49Dow Jones NewsAmbrx Biopharma Gets Fast Track Designation for ARX517 Cancer TreatmentNASDAQ:AMAMAmbrx Biopharma Inc
28/06/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202322h45Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
09/06/202322h12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AMAMAmbrx Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:AMAM

Kürzlich von Ihnen besucht

LSE
SUES
Is Sus Em Sri
EU
K993S
K993S
LSE
NBPO
New Britain Palm Oil
NASDAQ
SNWL
Sonicwall
LSE
PAN
Pan Euro
LSE
AAZ
Anglo Asian Mining
BIT
I10079
IT0005590812 20240603 44
NASDAQ
HYZN
Hyzon Motors
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten